Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept customized interval versus standard treat-and-extend in fluid-free neovascular age-related macular degeneration
2022-000690-73Phase 4Terminated
- Sponsor
- Bayer
- Start
- Jul 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of aflibercept in exudative macular degeneration (2 arms), sponsored by Bayer. Primary endpoint: Change in best-corrected visual acuity. Started Jul 2022; status: terminated.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2022-000690-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000690-73.